107 related articles for article (PubMed ID: 16036529)
1. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Scand J Gastroenterol; 2005 Jun; 40(6):688-96. PubMed ID: 16036529
[TBL] [Abstract][Full Text] [Related]
2. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
Hepatology; 2007 Nov; 46(5):1357-64. PubMed ID: 17657816
[TBL] [Abstract][Full Text] [Related]
3. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
[TBL] [Abstract][Full Text] [Related]
4. Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma.
Takeyasu M; Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2012 Aug; 84(8):1199-207. PubMed ID: 22711347
[TBL] [Abstract][Full Text] [Related]
5. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients.
Ikeda K; Arase Y; Kobayashi M; Saitoh S; Someya T; Hosaka T; Sezaki H; Akuta N; Suzuki Y; Suzuki F; Kumada H
Dig Dis Sci; 2006 Mar; 51(3):603-9. PubMed ID: 16614974
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial.
Xie Y; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
Hepatobiliary Pancreat Dis Int; 2005 May; 4(2):213-9. PubMed ID: 15908318
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy.
Iwasaki Y; Takaguchi K; Ikeda H; Makino Y; Araki Y; Ando M; Kobashi H; Kobatake T; Tanaka R; Tomita M; Senoh T; Kawaguchi M; Shimoe T; Manabe K; Kita K; Shimamura J; Sakaguchi K; Shiratori Y
Liver Int; 2004 Dec; 24(6):603-10. PubMed ID: 15566511
[TBL] [Abstract][Full Text] [Related]
9. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
J Med Virol; 2007 Oct; 79(10):1485-90. PubMed ID: 17705189
[TBL] [Abstract][Full Text] [Related]
10. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP.
Murashima S; Tanaka M; Haramaki M; Yutani S; Nakashima Y; Harada K; Ide T; Kumashiro R; Sata M
Dig Dis Sci; 2006 Apr; 51(4):808-12. PubMed ID: 16615008
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
12. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan.
Chuang WL; Dai CY; Chen SC; Lee LP; Lin ZY; Hsieh MY; Wang LY; Yu ML; Chang WY
Liver Int; 2004 Dec; 24(6):595-602. PubMed ID: 15566510
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a.
Tabaru A; Narita R; Hiura M; Abe S; Otsuki M
Am J Gastroenterol; 2005 Apr; 100(4):862-7. PubMed ID: 15784033
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
16. Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center.
Ikeda K; Arase Y; Saitoh S; Kobayashi M; Someya T; Hosaka T; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Kumada H
Intervirology; 2006; 49(1-2):82-90. PubMed ID: 16166794
[TBL] [Abstract][Full Text] [Related]
17. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial.
Fartoux L; Degos F; Trépo C; Goria O; Calès P; Tran A; Buffet C; Poynard T; Capron D; Raabe JJ; Roulot D; Naveau S; Grange JD; Poupon RE; Poupon R; Serfaty L
Clin Gastroenterol Hepatol; 2007 Apr; 5(4):502-7. PubMed ID: 17261383
[TBL] [Abstract][Full Text] [Related]
18. An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study.
Manolakopoulos S; Bethanis S; Liapi C; Stripeli F; Sklavos P; Margeli A; Christidou A; Katsanika A; Vogiatzakis E; Tzourmakliotis D; Theocharis S
BMC Gastroenterol; 2007 May; 7():17. PubMed ID: 17540037
[TBL] [Abstract][Full Text] [Related]
19. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.
Arase Y; Ikeda K; Tsubota A; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2004; 47(6):355-61. PubMed ID: 15564748
[TBL] [Abstract][Full Text] [Related]
20. Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma.
Sakaguchi Y; Kudo M; Fukunaga T; Minami Y; Chung H; Kawasaki T
Intervirology; 2005; 48(1):64-70. PubMed ID: 15785092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
